Sofregen Medical Raises $6.2 Million In Series A Funding From Polaris Partners And Other Founding Investors

Financing to Date Exceeds $11 Million to Develop Silk-Based Medical Technologies

MEDFORD, Mass.--(BUSINESS WIRE)--Sofregen Medical Inc. (Sofregen), the company pioneering silk-based medical technologies to address soft tissue defects, today announced a $6.2 million Series A financing from Polaris Partners and other founding investors who previously seeded the company. Founded in 2014 to advance technology developed at Tufts University and the University of Pittsburgh, Sofregen has a variety of silk-based innovations currently in development and will use the funding to further its platform.

“We are excited about Sofregen’s vision of building a platform of silk-based products that address some of the most sensitive medical and aesthetic needs of millions of patients worldwide”

“The opportunities to use silk as the foundational material in repairing soft tissue are extremely promising,” said Howard Weisman, Chairman of Sofregen. “Silk fiber has been proven to be strong, flexible and biocompatible in a wide variety of surgical procedures. With this technology, we will be providing better solutions for physicians and greater hope for patients.”

The company, which has previously raised $1.6 million from seed investors, has also agreed to terms on $3.5 million in bank debt financing, bringing total funding to $11.3 million.

“We are excited about Sofregen’s vision of building a platform of silk-based products that address some of the most sensitive medical and aesthetic needs of millions of patients worldwide,” said Polaris Partner, Amir Nashat, Ph.D., and member of the Sofregen Board. “We are delighted to work with a proven partner such as Howard Weisman again, and his team is well-positioned to translate this superior science into a market reality.”

About Sofregen Medical
Founded in 2014 to advance technology developed at Tufts University and the University of Pittsburgh, Sofregen is a pioneer in the use of silk, nature’s healing fiber, in a variety of forms to help physicians address soft tissue defects, giving patients a fresh start, restoring confidence, and improving quality of life. Sofregen is committed to restoring function and cosmetic appearance for medical and aesthetic patients worldwide.

About Polaris Partners
Polaris Partners invests in exceptional technology and healthcare companies across all stages of their life cycles. With offices in Boston, San Francisco, and Dublin, Polaris partners globally with an unparalleled network of repeat entrepreneurs, top scientists and emerging innovators who are making significant contributions in their fields and improving the way in which people live and work. For more information, please visit www.polarispartners.com.